시장보고서
상품코드
1878863

공포증 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 공포증 종류별, 치료법별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

Phobia Treatment Market - Global Industry Size, Share, Trends, Opportunity and Forecast, By Type of Phobia, By Treatment, By End User, By Region, By Competition, 2020-2030F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 183 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 공포증 치료 시장은 2024년에 19억 2,000만 달러로 평가되었으며, 2030년까지 CAGR 5.78%로 성장하여 26억 9,000만 달러에 달할 것으로 예측됩니다.

공포증 치료에는 특정 사물, 상황 또는 활동에 대한 강렬하고 비합리적인 두려움을 완화하기 위해 고안된 다양한 치료적 개입이 포함됩니다. 이러한 치료는 주로 인지행동치료, 노출치료 등의 심리치료를 주축으로 하며, 관련 증상 관리를 위해 항불안제, 항우울제 등의 약물 치료를 병행하는 경우가 많습니다. 시장 성장은 주로 전 세계적으로 정신질환에 대한 인식 개선과 편견 해소, 증거 기반 심리 중재에 대한 수요 증가, 디지털 기술 및 가상현실(VR) 기반 솔루션을 포함한 치료 방법의 지속적인 발전으로 뒷받침되고 있습니다.

시장 개요
예측 기간 2026-2030년
시장 규모 : 2024년 19억 2,000만 달러
시장 규모 : 2030년 26억 9,000만 달러
CAGR : 2025-2030년 5.78%
가장 빠르게 성장하는 부문 치료
최대 시장 북미

주요 시장 촉진요인

주요 시장 과제

주요 시장 동향

자주 묻는 질문

  • 세계의 공포증 치료 시장 규모는 어떻게 되나요?
  • 공포증 치료 시장에서 가장 빠르게 성장하는 부문은 무엇인가요?
  • 공포증 치료 시장의 최대 시장은 어디인가요?
  • 공포증 치료에 사용되는 주요 치료법은 무엇인가요?
  • 공포증 치료 시장의 성장 요인은 무엇인가요?

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 공포증 치료 시장 전망

  • 시장 규모 및 예측
    • 금액별
  • 시장 점유율과 예측
    • 공포증 종류별(동물공포증, 고소공포증, 광장공포증, 폐소공포증, 사회공포증, 기타)
    • 치료법별(심리요법, 약물요법)
    • 최종사용자별(병원, 정신과클리닉, 공포증 치료 센터, 기타)
    • 지역별
    • 기업별(2024)
  • 시장 맵

제6장 북미의 공포증 치료 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 북미 : 국가별 분석
    • 미국
    • 캐나다
    • 멕시코

제7장 유럽의 공포증 치료 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 유럽 : 국가별 분석
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인

제8장 아시아태평양의 공포증 치료 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주

제9장 중동 및 아프리카의 공포증 치료 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 중동 및 아프리카 : 국가별 분석
    • 사우디아라비아
    • 아랍에미리트
    • 남아프리카공화국

제10장 남미의 공포증 치료 시장 전망

  • 시장 규모 및 예측
  • 시장 점유율과 예측
  • 남미 : 국가별 분석
    • 브라질
    • 콜롬비아
    • 아르헨티나

제11장 시장 역학

  • 성장 촉진요인
  • 과제

제12장 시장 동향과 발전

  • 인수합병
  • 제품 출시
  • 최근 동향

제13장 세계의 공포증 치료 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

  • 업계내 경쟁
  • 신규 참여의 가능성
  • 공급업체의 능력
  • 고객의 능력
  • 대체품의 위협

제15장 경쟁 구도

  • Sanofi S.A
  • Cambrex Corporation
  • Teva Pharmaceutical Industries Ltd
  • Midas Pharma GmbH
  • Harman Finochem Ltd
  • Pfizer Inc.
  • AstraZeneca, Plc.
  • Eli Lilly and Company
  • Lupin Limited
  • GlaxoSmithKline plc

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

KSM 25.12.15

The Global Phobia Treatment Market , valued at USD 1.92 Billion in 2024, is projected to experience a CAGR of 5.78% to reach USD 2.69 Billion by 2030. Phobia treatment encompasses a variety of therapeutic interventions designed to alleviate intense and irrational fears of specific objects, situations, or activities. These treatments primarily involve psychotherapy, such as cognitive-behavioral therapy and exposure therapy, frequently complemented by pharmacotherapy, including anxiolytics and antidepressants, to manage associated symptoms. The market's growth is largely supported by increasing global awareness and destigmatization of mental health conditions, a rising demand for evidence-based psychological interventions, and ongoing advancements in therapeutic modalities, including digital and virtual reality-based solutions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.92 Billion
Market Size 2030USD 2.69 Billion
CAGR 2025-20305.78%
Fastest Growing SegmentTherapy
Largest MarketNorth America

Key Market Drivers

The increasing prevalence of phobia-related disorders and growing awareness of mental health are pivotal in driving the global phobia treatment market. As a subset of anxiety disorders, the widespread incidence of these conditions creates substantial demand for therapeutic interventions. According to the World Health Organization, in its September 2025 "Anxiety disorders" fact sheet, 359 million people globally were affected by anxiety disorders in 2021, signifying a pervasive need for effective treatment. This underlying requirement is actively met as growing awareness and acceptance encourage individuals to seek professional help. Proactive governmental and healthcare initiatives further bolster this shift away from stigmatization.

Key Market Challenges

The persistent limited access to specialized mental health professionals globally constitutes a significant challenge for the expansion of the phobia treatment market. Despite the high prevalence of phobias and increasing mental health awareness, a substantial portion of the affected population struggles to receive appropriate care. This access barrier directly curtails the availability and delivery of effective therapeutic interventions, such as cognitive-behavioral therapy and exposure therapy. According to the World Health Organization's Mental Health Atlas 2024, the global median for mental health workers was 13 per 100,000 people, but this figure demonstrates extreme disparities, with lower-income countries reporting as few as 1.1 specialized mental health workers per 100,000 people compared to 67.2 in high-income countries. Such a pronounced shortage of trained professionals, particularly in underserved regions, means that many individuals seeking treatment cannot initiate or sustain their care, thereby restricting the market's potential for growth and the overall reach of phobia treatment services.

Key Market Trends

The integration of Virtual Reality (VR) exposure therapy represents a transformative trend in the global phobia treatment market. This innovative approach provides immersive and controllable environments, allowing patients to safely and repeatedly confront their specific phobias, thereby overcoming the practical and logistical challenges associated with traditional in-vivo exposure. The growing clinical acceptance of this modality is evident, with the American Psychiatric Association, in its October 2023 article "Transforming Mental Health Care: The Rise of VR/AR Applications in Psychiatry," highlighting VR's broad applications in psychiatry, including its common use in immersive exposure therapy for phobias. This underscores the increasing relevance and endorsement of VR within the professional mental healthcare community.

Key Market Players

  • Sanofi S.A
  • Cambrex Corporation
  • Teva Pharmaceutical Industries Ltd
  • Midas Pharma GmbH
  • Harman Finochem Ltd
  • Pfizer Inc.
  • AstraZeneca, Plc.
  • Eli Lilly and Company
  • Lupin Limited
  • GlaxoSmithKline plc

Report Scope:

In this report, the Global Phobia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Phobia Treatment Market , By Type of Phobia:

  • Zoophobia
  • Acrophobia
  • Agoraphobia
  • Claustrophobia
  • Social Phobia
  • Others

Phobia Treatment Market , By Treatment:

  • Therapy
  • Medication

Phobia Treatment Market , By End User:

  • Hospitals
  • Psychiatry Clinics
  • Phobia Treatment Centers
  • Others

Phobia Treatment Market , By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Phobia Treatment Market .

Available Customizations:

Global Phobia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Phobia Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type of Phobia (Zoophobia, Acrophobia, Agoraphobia, Claustrophobia, Social Phobia, Others)
    • 5.2.2. By Treatment (Therapy, Medication)
    • 5.2.3. By End User (Hospitals, Psychiatry Clinics, Phobia Treatment Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Phobia Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Phobia
    • 6.2.2. By Treatment
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Phobia Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type of Phobia
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Phobia Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type of Phobia
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Phobia Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type of Phobia
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By End User

7. Europe Phobia Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Phobia
    • 7.2.2. By Treatment
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Phobia Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type of Phobia
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By End User
    • 7.3.2. France Phobia Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type of Phobia
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Phobia Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type of Phobia
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Phobia Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type of Phobia
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Phobia Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type of Phobia
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By End User

8. Asia Pacific Phobia Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Phobia
    • 8.2.2. By Treatment
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Phobia Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type of Phobia
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By End User
    • 8.3.2. India Phobia Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type of Phobia
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Phobia Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type of Phobia
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Phobia Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type of Phobia
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Phobia Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type of Phobia
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By End User

9. Middle East & Africa Phobia Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Phobia
    • 9.2.2. By Treatment
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Phobia Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type of Phobia
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Phobia Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type of Phobia
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Phobia Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type of Phobia
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By End User

10. South America Phobia Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Phobia
    • 10.2.2. By Treatment
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Phobia Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type of Phobia
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Phobia Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type of Phobia
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Phobia Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type of Phobia
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Phobia Treatment Market : SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Sanofi S.A
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Cambrex Corporation
  • 15.3. Teva Pharmaceutical Industries Ltd
  • 15.4. Midas Pharma GmbH
  • 15.5. Harman Finochem Ltd
  • 15.6. Pfizer Inc.
  • 15.7. AstraZeneca, Plc.
  • 15.8. Eli Lilly and Company
  • 15.9. Lupin Limited
  • 15.10. GlaxoSmithKline plc

16. Strategic Recommendations

17. About Us & Disclaimer

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제